7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification
Key Takeaways
- Chronic GVHD is defined by clinical morphology and organ findings, not a day +100 cutoff; acute-type features after day 100 remain late acute GVHD, while overlap includes both acute and chronic features.
- Phase 2 of chronic GVHD biology centers on thymic injury: destruction of medullary thymic epithelial cells impairs AIRE expression and central negative selection, letting autoreactive and alloreactive donor T-cell clones escape into the periphery.
- Regulatory T-cell depletion and excess B-cell activating factor (BAFF) relative to naive B cells drive autoantibody production against targets including PDGFR-alpha, nuclear antigens, and H-Y minor histocompatibility antigens.
- Phase 3 fibrosis is driven by TGF-beta and PDGF signaling through ROCK2 and SMAD2/3, which transdifferentiate fibroblasts into alpha-SMA-expressing myofibroblasts that deposit types I and III collagen - explaining cutaneous sclerosis, fascial tightening, and bronchiolar obliteration.
- This loss-of-tolerance and fibrotic biology, rather than the predominantly cytotoxic alloreactivity of acute GVHD, is what makes chronic GVHD resemble an autoimmune syndrome.
Chronic GVHD: NIH Consensus Diagnostic Criteria & Clinical Manifestations
Quick Clinical Summary: Chronic Graft-versus-Host Disease (cGVHD) is the leading cause of late non-relapse morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT), affecting 30% to 70% of long-term survivors. Driven by thymic epithelial injury, loss of central and peripheral immune tolerance, auto- and alloreactive T- and B-cell activation, and progressive TGF-beta/PDGF-mediated fibrogenesis, cGVHD mimics systemic autoimmune disorders such as scleroderma, Sjogren's syndrome, and lichen planus. The National Institutes of Health (NIH) Consensus Criteria have eliminated the historical "Day +100" time threshold, establishing rigorous clinical definitions for Classic Chronic GVHD and Overlap Syndrome based on diagnostic and distinctive organ features across eight major organ systems.
1. Immunological Pathophysiology: The Three-Phase Model
Unlike acute GVHD, which is primarily an acute cytolytic storm driven by donor mature T-cell alloreactivity against host histocompatibility antigens, chronic GVHD develops as a complex, multistage autoimmune and fibrotic disorder. The contemporary paradigm organizes cGVHD pathogenesis into three interconnected phases:
THREE-PHASE PATHOPHYSIOLOGY OF cGVHD
[ Phase 1: Early Inflammation & Tissue Injury ]
* Conditioning (Chemo / TBI) + PAMPs / DAMPs + Acute GVHD residual inflammation
* Macrophage / DC activation -> Secretion of IL-1, TNF-alpha, IL-6, IFN-gamma
|
v
[ Phase 2: Chronic Inflammation, Thymic Injury & Loss of Immune Tolerance ]
* Medullary Thymic Epithelial Cell (mTEC) injury -> Loss of AIRE expression
* Impaired central negative selection -> Escape of autoreactive CD4+ & CD8+ T cells
* Deficiency of FoxP3+ Regulatory T cells (Tregs) -> Loss of peripheral tolerance
* Aberrant B-cell activation -> Elevated BAFF levels + Anti-PDGF receptor autoantibodies
* Germinal center Tfh & Th17 polarization -> Sustained pro-inflammatory signaling
|
v
[ Phase 3: Tissue Repair, Fibroblast Activation & Fibrosis ]
* Macrophages & Alloreactive T cells release TGF-beta & PDGF-alpha
* Activation of Rho-associated coiled-coil kinase 2 (ROCK2) signaling
* Transdifferentiation of resting fibroblasts into alpha-SMA+ contractile myofibroblasts
* Excessive extracellular matrix & collagen deposition -> Sclerosis, BOS, joint contractures
Phase 1: Early Inflammation and Endothelial/Epithelial Injury
- Triggers: High-dose myeloablative conditioning chemotherapy, total body irradiation (TBI), pre-existing acute GVHD damage, and translocation of pathogen-associated molecular patterns (PAMPs, e.g., LPS) and damage-associated molecular patterns (DAMPs, e.g., uric acid, HMGB1).
- Innate Activation: Recipient antigen-presenting cells (APCs) and donor-derived dendritic cells become hyperactivated, secreting inflammatory cytokines (TNF-alpha, IL-1, IL-6, IFN-gamma) and chemoattractants that recruit donor immune effectors into host target tissues (skin, liver, mucosal surfaces, lungs).
Phase 2: Thymic Damage, Immune Dysregulation & Loss of Tolerance
- Thymic Microenvironment Disruption: Conditioning and alloreactive donor T cells destroy medullary thymic epithelial cells (mTECs) and cortical epithelial niches. This impairs autoimmune regulator (AIRE) expression and disrupts central negative selection, permitting newly developing autoreactive and alloreactive donor T-cell clones to escape into the periphery.
- Regulatory T-Cell (Treg) Exhaustion: Peripheral CD4+CD25+FoxP3+ regulatory T cells undergo marked quantitative and qualitative depletion, failing to suppress autoreactive effector clones.
- B-Cell Dysregulation & Autoantibody Production: Excessive levels of B-cell activating factor (BAFF) relative to naive B-cell counts promote survival and hyperactivation of autoreactive B cells. Activated B cells act as potent APCs and secrete pathogenic autoantibodies directed against platelet-derived growth factor receptors (anti-PDGFR-alpha), nuclear antigens (ANA), and minor histocompatibility antigens (H-Y), driving sustained tissue signaling.
- Th17 and T Follicular Helper (Tfh) Shift: Disrupted immune balance promotes IL-17- and IL-21-secreting T-cell subsets, facilitating germinal center B-cell expansion and macrophage recruitment.
Phase 3: Tissue Repair, Fibroblast Activation & End-Stage Sclerosis
- Macrophage & Fibroblast Crosstalk: Infiltration of profibrotic M2 macrophages and alloreactive T cells leads to high local concentrations of Transforming Growth Factor-beta (TGF-beta) and Platelet-Derived Growth Factor (PDGF).
- Myofibroblast Differentiation: Engagement of TGF-beta receptors and PDGF receptors stimulates intracellular ROCK2 (Rho-associated coiled-coil kinase 2) and SMAD2/3 signaling cascades. Resting tissue fibroblasts transdifferentiate into alpha-smooth muscle actin (alpha-SMA)-expressing myofibroblasts.
- Extracellular Matrix Deposition: Myofibroblasts constitutively produce excessive types I and III collagen, fibronectin, and proteoglycans, obliterating normal tissue architecture. Microvascular rarefaction, deep fascial tightening, cutaneous sclerosis, and luminal obliteration in terminal bronchioles (BOS) result.
2. NIH Consensus Classification & Timing Definitions
Historically, GVHD occurring before Day +100 was termed "acute," and GVHD after Day +100 was termed "chronic." The NIH Consensus Conferences officially retired this arbitrary time-based threshold, replacing it with a clinicopathologic framework based strictly on clinical presentation and morphology.
| Category | Time of Onset | Acute GVHD Features | Chronic GVHD Features | Pathologic & Clinical Context |
|---|---|---|---|---|
| Classic Acute GVHD | Typically <= 100 days post-HCT (or post-DLI) | Present (erythematous maculopapular rash, secretory diarrhea, cholestatic jaundice) | Absent | Classic cytolytic target organ involvement. |
| Late-Onset Acute GVHD | >100 days post-HCT | Present (pure acute features: erythema, nausea/vomiting, large-volume diarrhea, hyperbilirubinemia) | Absent | Often precipitated by early immunosuppression taper or donor lymphocyte infusion (DLI). |
| Classic Chronic GVHD | Variable (typically >100 days, but can occur earlier) | Absent | Present (at least one diagnostic chronic feature OR distinctive feature + confirmation) | Sclerotic skin, oral lichenoid changes, BOS, keratoconjunctivitis sicca, fascial thickening. |
| Overlap syndrome | Variable (any time post-HCT) | Present | Present | Contains both acute- and chronic-GVHD features; prognosis and treatment depend on involved organs, activity, severity, infection and response rather than the label alone. |
NIH diagnostic rule: After excluding alternative causes, chronic GVHD requires at least one diagnostic manifestation, or one distinctive manifestation supported by pertinent biopsy, laboratory/radiologic testing, specialist assessment, or chronic-GVHD evidence in another organ. “Diagnostic” is the consensus term; not every such finding is pathognomonic.
Which immune mechanism contributes to chronic GVHD and helps distinguish its loss-of-tolerance/fibrotic biology from the predominantly acute epithelial injury pattern?